Management of Patients with Hepatitis B in Special Populations

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Feb 17

PMID 25684938

Citations 15

Authors

Evangelos Cholongitas

Konstantinos Tziomalos

Chrysoula Pipili

Affiliations

Soon will be listed here.

Abstract

The development of effective nucleos(t)ide analogs (NAs) against hepatitis B virus (HBV) has improved the outcome of patients with chronic hepatitis B (CHB). This review updates issues related to the management of CHB patients included in special populations. Entecavir (ETV) and tenofovir (TDF) represent the currently recommended first-line NAs in patients with HBV decompensated cirrhosis. The combination of HBV immunoglobulin (usually for a finite duration) and NA is considered the standard of care for prophylaxis against HBV recurrence after liver transplantation. TDF is the best choice for hemodialysis patients and in patients with chronic kidney disease with nucleoside resistance. ETV and telbivudine are the preferred options in naïve renal transplant recipients and with low viremia levels, respectively. All hepatitis B surface antigen (HBsAg)-positive candidates should be treated with NAs before renal transplantation to achieve undetectable HBV DNA at the time of transplantation. Conventional interferon or NAs can also be used in children, on the basis of well-established therapeutic indication. Pregnant women at high risk of perinatal transmission could be treated with lamivudine, telbivudine or TDF in the last trimester of pregnancy. HBsAg-positive patients under immunosuppression should receive NA pre-emptively (regardless of HBV DNA levels) up to 12 mo after its cessation. In HBsAg negative, anti-HBc positive patients under immunosuppression, further studies are needed to form a final conclusion; however, it seems that anti-HBV prophylaxis is justified in such patients with hematological diseases and/or for those receiving rituximab-containing regimens, regardless of their anti-HBs or serum HBV DNA status.

Citing Articles

Management of hepatitis B and C in special population.

Kulkarni A, Duvvuru N World J Gastroenterol. 2021; 27(40):6861-6873.

PMID: 34790011 PMC: 8567468. DOI: 10.3748/wjg.v27.i40.6861.

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases.

Park S, Choi C, Chun J, Lee H, Kim E, Park J Intest Res. 2020; 18(1):18-33.

PMID: 32013312 PMC: 7000641. DOI: 10.5217/ir.2019.09155.

Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers.

Adjei C, Stutterheim S, Naab F, Ruiter R PLoS One. 2019; 14(12):e0225830.

PMID: 31794577 PMC: 6890212. DOI: 10.1371/journal.pone.0225830.

Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease.

Yaccob A, Mari A Frontline Gastroenterol. 2019; 10(3):309-315.

PMID: 31281626 PMC: 6583566. DOI: 10.1136/flgastro-2018-101037.

INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids.

Arora A, Anand A, Kumar A, Singh S, Aggarwal R, Dhiman R J Clin Exp Hepatol. 2018; 8(4):403-431.

PMID: 30568345 PMC: 6286881. DOI: 10.1016/j.jceh.2018.06.010.

References

Picciotto F, Tritto G, Lanza A, Addario L, De Luca M, Di Costanzo G . Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46(3):459-65. DOI: 10.1016/j.jhep.2006.10.017. View

Wesdorp D, Knoester M, Braat A, Coenraad M, Vossen A, Claas E . Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol. 2013; 58(1):67-73. DOI: 10.1016/j.jcv.2013.06.035. View

Brown Jr R, Verna E, Pereira M, Tilson H, Aguilar C, Leu C . Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012; 57(5):953-9. DOI: 10.1016/j.jhep.2012.06.031. View

Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E . Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005; 84(5):313-322. DOI: 10.1097/01.md.0000180792.80212.5e. View

Ye X, Su Q . Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013; 19(39):6665-78. PMC: 3801384. DOI: 10.3748/wjg.v19.i39.6665. View

Hyun J, Seo Y, Yoon E, Kim T, Kim D, Kang H . Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int. 2011; 32(4):656-64. DOI: 10.1111/j.1478-3231.2011.02676.x. View

Cholongitas E, Papatheodoridis G, Burroughs A . Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2009; 52(2):272-9. DOI: 10.1016/j.jhep.2009.11.009. View

Wong V, Chan F . Regression of cirrhosis with long-term tenofovir treatment. Gastroenterology. 2013; 145(2):481-2. DOI: 10.1053/j.gastro.2013.06.019. View

Chopra A, Cantarovich M, Bain V . Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation. 2011; 91(12):1305-9. DOI: 10.1097/TP.0b013e31821bad1b. View

10.

Fabrizi F, MARTIN P, Dixit V, Kanwal F, Dulai G . HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5(12):2913-21. DOI: 10.1111/j.1600-6143.2005.01113.x. View

11.

McMahon B, Alward W, Hall D, Heyward W, Bender T, Francis D . Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985; 151(4):599-603. DOI: 10.1093/infdis/151.4.599. View

12.

Calvaruso V, Craxi A . Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?. Liver Int. 2013; 34 Suppl 1:85-90. DOI: 10.1111/liv.12395. View

13.

Chen C, Lin C, Hu T, Hung C, Tseng P, Wang J . Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014; 60(6):1127-34. DOI: 10.1016/j.jhep.2014.02.013. View

14.

Roche B, Samuel D . Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int. 2012; 32 Suppl 1:120-8. DOI: 10.1111/j.1478-3231.2011.02714.x. View

15.

Jonas M, Block J, Haber B, Karpen S, London W, Murray K . Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010; 52(6):2192-205. DOI: 10.1002/hep.23934. View

16.

Chan H, Chen Y, Gane E, Sarin S, Suh D, Piratvisuth T . Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012; 19(10):732-43. DOI: 10.1111/j.1365-2893.2012.01600.x. View

17.

Cholongitas E, Vasiliadis T, Goulis I, Fouzas I, Antoniadis N, Papanikolaou V . Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat. 2014; 22(7):574-80. DOI: 10.1111/jvh.12362. View

18.

Hall A, Hendry B, Nitsch D, Connolly J . Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011; 57(5):773-80. DOI: 10.1053/j.ajkd.2011.01.022. View

19.

Singal A, Fontana R . Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012; 35(6):674-89. DOI: 10.1111/j.1365-2036.2011.04990.x. View

20.

Pipili C, Cholongitas E, Papatheodoridis G . Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther. 2013; 39(1):35-46. DOI: 10.1111/apt.12538. View